Isofol Medical AB (publ) appoints Carnegie Investment Bank AB (publ) to Financial advisor
GOTHENBURG, Sweden, February 27, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), announced today that the company […]
English
Isofol Reports All Employees Participate in Newly Created Share Warrant Program
GOTHENBURG, Sweden, February 1, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that all senior
Isofol has participated in the Empowered Patient Podcast
In honor of World Cancer Day on February 4, we would like to share a podcast where Anders Rabbe, CEO
Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin
GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from
First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer
GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first
Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development
GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the recruitment of
Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors
GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of
Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer
GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced initiation of the
New Chairman and extended board at Isofol Medical AB (publ)
Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling an Extraordinary General Meeting on Wednesday
Patent approved in the United States for Isofol’s drug candidate arfolitixorin
The patent now approved in the United States expires in 2037 and covers both the Active Pharmaceutical Ingredient (arfolitixorin hemisulfate),